Stocks Comparison
Cellyan Biotechnology vs McKesson: revenue, profit, margins and growth compared
Cellyan Biotechnology brought in $20.3M of revenue in fiscal 2025, McKesson $403.4B in fiscal 2026. Revenue changed by +21.7% at Cellyan Biotechnology and +12.4% at McKesson on the year before, so Cellyan Biotechnology grew faster. Cellyan Biotechnology kept -0.1% of its revenue as net profit, McKesson 1.2%. Free cash flow was $499.3K at Cellyan Biotechnology and $5.7B at McKesson.
Side by side, latest fiscal year
| HKPD | MCK | |
|---|---|---|
| Fiscal year ended | FY2025 (March 31, 2025) | FY2026 (March 31, 2026) |
| Revenue | $20.3M | $403.4B |
| Revenue growth | +21.7% | +12.4% |
| Net income | -$27.1K | $4.8B |
| Net margin | -0.1% | 1.2% |
| Free cash flow | $499.3K | $5.7B |
| Free cash flow margin | 2.5% | 1.4% |
| Earnings per share (diluted) | -$0.00 | $38.38 |
| Cash | $748.7K | $4B |
| Debt | $1.9M | $6.5B |
| Price to earnings | n/a | 22.6 |
| Market value | $5.4M | $101B |
| Dividend yield | n/a | 0.37% |
| Rank by revenue in sector | #434 of 646 · Health care | #2 of 646 · Health care |
Over the years
Questions about Cellyan Biotechnology and McKesson
Which is bigger by revenue, Cellyan Biotechnology or McKesson?
McKesson is bigger by revenue: $403.4B in fiscal 2026, against $20.3M for Cellyan Biotechnology in fiscal 2025.
Which keeps more of its revenue as profit, Cellyan Biotechnology or McKesson?
Cellyan Biotechnology had a net margin of -0.1% in fiscal 2025; McKesson had 1.2% in fiscal 2026.
Which grew revenue faster, Cellyan Biotechnology or McKesson?
In their latest fiscal years revenue changed by +21.7% at Cellyan Biotechnology and +12.4% at McKesson.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.